N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis
7% specific in predicting nonalcoholic steatohepatitis
and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy.
Both studies involved people with nonalcoholic steatohepatitis
(NASH), an aggressive disease characterised by fat in the liver.
Randomised clinical trial: the beneficial effects of VSL#3 in obese children with nonalcoholic steatohepatitis
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis
(NASH) Drug market.
VIENNA -- Pooled analysis of data from three controlled trials provides further evidence to support the use of vitamin E in the treatment of nonalcoholic steatohepatitis
Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-[alpha] and IL-6 in the pathogenesis of nonalcoholic steatohepatitis
Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis
In industrialized countries, the main causes of liver injury leading to fibrosis include chronic hepatitis virus infection, excess alcohol consumption and, increasingly, nonalcoholic steatohepatitis
In contrast, up to 25% of patients may progress from simple steatosis to nonalcoholic steatohepatitis
(NASH), which is characterized by necro-inflammation and/or varying degrees of fibrosis.
The condition, nonalcoholic steatohepatitis
(NASH), resembles alcoholic liver disease, but occurs in people who drink little or no alcohol.